Kura Oncology KURA

Troy E. Wilson, Ph.D., J.D., co-founded Kura Oncology, Inc. and has served as our President and Chief Executive Officer since 2014, as the Chairman of our Board of Directors since March 2015, and as our principal financial officer since February 2022. Dr. Wilson served as President and Chief Executive Officer of Araxes Pharma LLC (Araxes) from 2012 to 2019 and currently serves as Executive Chairman and Sole Manager of Araxes. He served as President and Chief Executive Officer of Avidity Biosciences, Inc. (Avidity) from 2012 to 2019, when it was privately held, and as a member of Avidity's Board of Directors and as Chairman of the Board from 2012 and 2019, respectively, until Avidity's acquisition by Novartis AG in February 2026. Avidity became a public company in 2020. Dr. Wilson served as the President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., a privately held biopharmaceutical company, from 2007 to 2012, until its acquisition by Takeda. He has served as a member of the Boards of Directors of Puma Biotechnology, Inc., a publicly held biopharmaceutical company, since 2013, Atrium Therapeutics, Inc., a publicly held biopharmaceutical company, since February 2026, and Cipher Genetics, a privately held company, since September 2025. He has been Chairman of the Board and a member of the Board of Directors of Cartography Biosciences, Inc., a privately held biotechnology company, since October 2024, and Chairman of the Board and a member of the Board of Directors of Montara Therapeutics, a privately held biotechnology company, since February 2025. Dr. Wilson holds a J.D. from New York University and a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.

Brian Powl has served as our Chief Commercial Officer since August 2023. Mr. Powl joined Kura with more than 20 years of experience in building commercial brands in hematology and oncology, with a focus on developing and executing patient-focused strategies across sales, marketing and market access for global biotechnology and pharmaceutical products. Most recently, he served as Chief Commercial Officer at Fate Therapeutics, Inc., a publicly held biopharmaceutical company, from June 2022 to August 2023, where he led the commercialization efforts for the company's oncology and immunology portfolio. Previously, Mr. Powl was Senior Vice President, Commercial Development & Marketing at MEI Pharma, Inc., a publicly held biotechnology company, from 2020 to June 2022, where he led the commercialization efforts of a late-stage small molecule program in B-cell malignancies. Earlier in his career, from 2011 to 2020, Mr. Powl held positions of increasing responsibility at Celgene Corporation including Vice President, Global Commercial CAR T lead, where he led the commercialization efforts of ABECMA and BREYANZI and served as the Global Marketing lead for Celgene's flagship multiple myeloma franchise during the life cycle expansion of REVLIMID and POMALYST. Mr. Powl earned his B.S. in Biochemistry from the University of California, San Diego and his M.B.A. in Healthcare Management/Marketing from the Wharton School at the University of Pennsylvania.

Kathleen Ford has served as our Chief Operating Officer since August 2019, and previously served as a consultant to us from January 2019 to August 2019. Prior to joining us, from 2012 to 2017, she served as Senior Vice President, Head of Global Clinical Operations, at Merck Serono, a division of Merck KGaA, where she led clinical and development operations toward successful drug registrations in both the United States and Europe. From 2002 to 2009, she served in roles of increasing responsibility at Millennium Pharmaceuticals, Inc., a privately held pharmaceutical company, most recently as Vice President, Clinical Operations, where she led the global operational management of clinical trial activities in all phases of development. From 1993 to 2002, she served as Director of Clinical Operations at Alkermes plc, a publicly held biopharmaceutical company, where she managed the clinical development for two product approvals. Ms. Ford earned her R.N. from Massachusetts General Hospital School of Nursing and her B.S.N. from Fitchburg State College.

Faheem Hasnain, has served as a member of our Board of Directors since April 2015 and as our Lead Independent Director since March 2020. Mr. Hasnain co-founded and has served as Chairman of the Board of Directors of Gossamer Bio, Inc. (Gossamer), a publicly held biopharmaceutical company with specific focus on the development and commercialization of seraluntinib for the treatment of pulmonary arterial hypertension, since 2018 and as Chief Executive Officer and President since 2020. Mr. Hasnain previously served as Gossamer's Chief Executive Officer in 2018 and as Executive Chairman from 2018 to 2019. He has also served as Chairman of the Boards of Directors of Aspen Neuroscience, Inc., a privately held biotechnology company, since 2020, and Sling Therapeutics, Inc. (formerly VasaraGen, Inc.), a privately held biopharmaceutical company, since 2021. Mr. Hasnain was the President and Chief Executive Officer and on the Board of Directors of Receptos, Inc., a publicly held biopharmaceutical company, from 2010 until the company's acquisition by Celgene Corporation in 2015. Prior to that, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a publicly held biology driven antibody company with a focus in multiple sclerosis and oncology. He held that position from 2008 until the company's acquisition by Abbott Laboratories in 2010. Mr. Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. (PDL BioPharma), a publicly held biopharmaceutical company, from 2008 until Facet Biotech was spun off from PDL BioPharma in 2008. From 2004 to 2008, Mr. Hasnain served at Biogen Inc. (Biogen), a publicly held biotechnology company specializing in neurological disorders, autoimmune disorders and cancer, most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit. Prior to Biogen, Mr. Hasnain held roles with Bristol Myers Squibb Co., where he was President of the Oncology Therapeutics Network, and at GlaxoSmithKline plc and its predecessor organizations. He was Chairman of the Board of Directors of Mirati Therapeutics, Inc., a publicly held biotechnology company, from 2019 to January 2024. Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.

Mary T. Szela, has served as a member of our Board of Directors since November 2018. Ms. Szela has served as Chief Executive Officer and President and a member of the Board of Directors of TriSalus Life Sciences, Inc. (formerly Surefire Medical, Inc.), a publicly held medical device company, since 2018. Ms. Szela served as Chief Executive Officer and as a member of the Board of Directors of Aegerion Pharmaceuticals, Inc. (Aegerion), a publicly held biopharmaceutical company, from 2016 through Aegerion's merger with QLT Inc. to form Novelion Therapeutics Inc., a publicly held biopharmaceutical company, where, until 2017, Ms. Szela served as Chief Executive Officer and as a member of the Board of Directors. Ms. Szela served as the Chief Executive Officer of Melinta Therapeutics, Inc., a publicly held antibiotic development company, from 2013 to 2015. Previously, Ms. Szela joined Abbott Laboratories (Abbott) in 1987 and held several leadership positions, including Senior Vice President of Global Strategic Marketing from 2010 to 2012 and Senior Vice President of the company's U.S. pharmaceutical business from 2008 to 2009. Prior to Abbott, Ms. Szela worked for the University of Illinois Hospital. She has served as a member of the Boards of Directors of Absci Corporation, a publicly held generative AI drug creation company, since July 2025 and Averin Capital Acquisition Corp., a multi-stage investment firm, since February 2026. Ms. Szela previously served on the Boards of Directors of Coherus Oncology, Inc. (formerly Coherus BioSciences, Inc.), a publicly traded biopharmaceutical company, from 2014 until August 2021; Prometheus Biosciences, Inc., a publicly traded biopharmaceutical company, from February 2021 until its merger with Splash Merger Sub, Inc., a wholly owned subsidiary of Merck & Co, Inc., in June 2023; Alimera Sciences, Inc., a publicly traded drug development company, from 2018 until June 2021; and Omega Therapeutics, Inc., a publicly traded development-stage biotechnology company, from 2019 until March 2025. Ms. Szela earned a B.S. in Nursing and an M.B.A. from the University of Illinois.

Carol Schafer, has served as a member of our Board of Directors since June 2021. Ms. Schafer has served as the Managing Partner of Hyphen Advisors, LLC, an advisory firm, since 2018. Ms. Schafer previously worked at Wells Fargo Securities from 2007 to 2018, most recently as Vice Chair, Equity Capital Markets. Prior to that, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals, Inc. from 2003 to 2007. Earlier, she held positions of increasing responsibility at J.P. Morgan, most recently serving as Managing Director of Equity Capital Markets. Ms. Schafer has served on the Boards of Directors of Insmed Incorporated, a publicly held biopharmaceutical company, since 2020, Immunome, Inc., a publicly held biotechnology company, since January 2024, and OMass Therapeutics, a privately held biotechnology company, since July 2025. Ms. Schafer previously served on the Boards of Directors of Idera Pharmaceuticals, Inc., a publicly held biopharmaceutical company, from 2018 to September 2022, Five Prime Therapeutics, Inc., a publicly held oncology company, from 2019 until its acquisition by Amgen in April 2021, and Repare Therapeutics Inc., a publicly held oncology company, from 2019 to January 2026. She holds an M.B.A from New York University's Stern School of Business and a B.A. from Boston College.

Thomas Malley, has served as a member of our Board of Directors since October 2015. Mr. Malley has served as President of Mossrock Capital, LLC (Mossrock), a private investment firm, since 2007. He worked for Janus Mutual Funds (Janus) in positions of increasing responsibility from 1991 to 2007. From 1999 to 2007, Mr. Malley served as the portfolio manager of the Janus Global Life Sciences Fund and also led the Janus healthcare team of analysts. From 1991 to 1998, Mr. Malley served as an equity analyst for Janus covering, among others, healthcare and biotechnology stocks. Mr. Malley has served on the Board of Directors of Kiniksa Pharmaceutical Corp., a publicly held biopharmaceutical company, since 2016, and previously served on the Board of Directors of BeiGene, Ltd., a publicly held biotechnology company, from 2016 to January 2024. Mr. Malley has served on the Board of Directors of LincSwitch Therapeutics, Inc., a privately held company, since September 2024. Mr. Malley also serves as Chair of the Board of Directors of Project C.U.R.E., a non-profit medical relief organization. Mr. Malley holds a B.S. in Biology from Stanford University.

Helen Collins, M.D., has served as a member of our Board of Directors since July 2021. Dr. Collins currently serves as Chief Medical Officer of Enliven Therapeutics, Inc., a publicly held biopharmaceutical company. Previously, Dr. Collins served in positions of increasing responsibility at Five Prime Therapeutics, Inc., a publicly held biotechnology company, from 2016 until the company's acquisition by Amgen in April 2021, most recently as Executive Vice President and Chief Medical Officer. Prior to that, from 2013 to 2016, Dr. Collins held positions of increasing responsibility at Gilead, most recently as Program and Clinical Lead for Gilead's GS-5829 (BET inhibitor) and GS-4059 (BTK inhibitor) programs, and Amgen from 2009 to 2013, most recently as Global Lead of Oncology Biosimilars. Dr. Collins has served on the Board of Directors of IO Biotech, Inc., a publicly held biotechnology company, since November 2023. Prior to her career in the biopharmaceutical industry, Dr. Collins practiced as a medical oncologist/hematologist for 12 years. She earned her M.D. from Johns Hopkins University School of Medicine, completing her residency at Johns Hopkins Hospital and oncology fellowship at Stanford University School of Medicine, and her B.A. from Bryn Mawr College.

Diane Parkshas served as a member of our Board of Directors since October 2019. From 2016 to 2018, Ms. Parks served as Senior Vice President, Head of U.S. Commercial for Kite Pharma, Inc., a publicly held biopharmaceutical company, which was acquired by Gilead Sciences, Inc. (Gilead), where she developed and executed the strategic plan for the commercial launch of Yescarta, the first CAR-T therapy approved for large B-cell lymphoma. From 2014 to 2015, Ms. Parks served as Vice President, Head of Global Marketing for Pharmacyclics, Inc., a publicly held biopharmaceutical company, which was acquired by AbbVie, Inc. (AbbVie), where she was responsible for the marketing strategy and launch of Imbruvica. From 2007 to 2014, she served as Vice President, Sales for Amgen Inc. (Amgen), a publicly held biotechnology company, where she successfully led the hospital and nephrology sales teams. From 1999 to 2005, she served in roles of increasing responsibility at Genentech, Inc., a publicly held biotechnology company, which was acquired by F. Hoffmann-La Roche AG, most recently as Senior Vice President, Specialty Biotherapeutics and Managed Care. She has served on the Boards of Directors of Soligenix, Inc., a publicly held biopharmaceutical company, since 2019, and Celularity Inc., a publicly held biopharmaceutical company, since June 2022. Ms. Parks previously served on the Boards of Directors of Calliditas Therapeutics AB, a publicly held biopharmaceutical company, from 2019 until its acquisition by Asahi Kasei Corp. in August 2024, and CTI BioPharma Corp., a publicly held biopharmaceutical company, from August 2021 until its acquisition by Swedish Orphan Biovitrum AB (Sobi) in June 2023. Ms. Parks earned an M.B.A. from Georgia State University and a B.S. from Kansas State University.

Michael J. Vasconcelles, has served as a member of our Board of Directors since September 2024. Dr. Vasconcelles has served as Head of Research and Development of Day One Biopharmaceuticals, Inc., a publicly traded biopharmaceutical company, since June 2025. Dr. Vasconcelles previously served as a Senior Advisor to the Frazier Life Sciences team, a venture capital firm, from 2019 until June 2025. From December 2022 to July 2024, he was Executive Vice President & Head of Research, Development, and Medical Affairs at ImmunoGen, Inc., now part of AbbVie. From 2019 to December 2022, he was the Chief Medical Officer and Head of the Medical and Scientific Organization at Flatiron Health, a wholly owned subsidiary of the Roche Group. From 2015 to 2019, he served as Chief Medical Officer at Unum Therapeutics, Inc. (now known as Cogent Biosciences, Inc.), a public biotechnology company. From 2012 to 2015, Dr. Vasconcelles was Senior Vice President and Global Head of the Oncology Therapy Area Unit at Millenium, The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals International Co. (Takeda). From 2000 to 2011, Dr. Vasconcelles held positions of increasing responsibility at Genzyme Corporation (Genzyme), including Group Vice President and the Global Therapeutic Area Head of Transplant and Oncology. After Sanofi's acquisition of Genzyme in 2011, Dr. Vasconcelles was Head of Personalized Medicine and Companion Diagnostics at Sanofi Transplant and Oncology until 2012. Dr. Vasconcelles has served as a non-executive director of Molecular Partners AG, a public clinical-stage biopharmaceutical company, since 2020, and a member of numerous scientific advisory boards within the biopharmaceutical industry. From 1996 to 2021, Dr. Vasconcelles taught as a clinical instructor at Harvard Medical School and was an associate physician at the Brigham and Women's Hospital and the Dana-Farber Cancer Institute. Dr. Vasconcelles received his B.A. and M.D. from Northwestern University.

On January 31, 2022, the Board of Directors of the Company appointed Thomas Doyle, the Company's Vice President, Finance, as the Company's Senior Vice President, Finance and Accounting and as the Company's principal accounting officer effective as of February 7, 2022. Mr. Doyle has served as the Company's Vice President, Finance since June 2021. Prior to joining the Company, Mr. Doyle served as Vice President of Finance for Zogenix Inc., a public biopharmaceutical company, from 2013 until June 2021. Prior to that, Mr. Doyle served as Controller for Peregrine Pharmaceuticals, Inc., a public oncology development and biomanufacturing company, as Director of Revenue and Cost Accounting for ISTA Pharmaceuticals, Inc., a public pharmaceutical company, and as the Director of Internal Audit and R&D Finance at Valeant Pharmaceuticals International, a public pharmaceutical company. Mr. Doyle is a certified public accountant and received his M.B.A. from California State University San Marcos and his B.S. in finance from San Diego State University. Thomas Doyle transitioned out of the role of Principal Accounting Officer with effect from 08th September 2026. He remains as Senior Vice President, Finance and Accounting.

Effective 08th September 2026, Jennifer Fulk was appointed as the Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer. Ms. Fulk served as Chief Financial Officer of Soleno Therapeutics, Inc., from March 2026 to May 2026. Previously, she served as Chief Operating Officer and Chief Financial Officer of 120Water, Inc., from September 2024 to October 2025 and as Chief Financial Officer of Talkspace, Inc., a publicly traded virtual behavioral healthcare company, from July 2021 to May 2024. Prior to that, Ms. Fulk spent more than 15 years at Eli Lilly and Company in finance executive roles, including as Chief Financial Officer, U.S. Bio-Medicines; Vice President, Investor Relations; Vice President, Global Finance and Integration, Elanco; and Chief Financial Officer, Lilly Germany, Austria, and Switzerland. In these roles, she led global finance teams, supported commercial and research and development organizations, and partnered closely with executive leadership on strategy, operations and capital markets engagement. Ms. Fulk earned her Bachelor of Science in Information Systems and a Master of Business Administration from Indiana University.

Mollie Leoni, M.D. has served as our Chief Medical Officer since January 2025. Dr. Leoni previously served as our Vice President, Clinical Development, from February 2020 to December 2021, Senior Vice President, Clinical Development, from January 2022 to June 2023, and Executive Vice President of Clinical Development from June 2023 to January 2025. Prior to joining us, from 2014 to 2020, she served in various roles at Kyowa Kirin Pharma, Inc., a biopharmaceutical and biotechnology company, most recently as Executive Director, Medical Sciences, where she was the medical and strategic lead for oncology mogamulizumab, which achieved international registration for cutaneous T-cell lymphoma. From 2011 to 2014, she served in various roles at IKARIA, Inc. (as acquired by Mallinckrodt Pharmaceuticals in 2013), a biopharmaceutical company, such as Director, Drug and Device Safety Physician and Head of Safety Operations. Dr. Leoni earned her M.D. from the University of Pennsylvania School of Medicine and her B.A. from the University of Pennsylvania, where she trained in bioethics before entering postgraduate training at Thomas Jefferson University Hospital.

Francis Burrows, Ph.D. has served as our Chief Scientific Officer since January 2025. Dr. Burrows previously served as our Vice President, Translational Research, from 2015 until January 2023, and our Senior Vice President of Translational Research, from January 2023 until January 2025. Dr. Burrows joined us with more than 20 years of experience in small and large biotechnology companies focusing on the biology of disease, primarily cancer, and the discovery, characterization and development of small molecule drugs. Prior to joining us, Dr. Burrows founded two biotechnology startup companies: Conforma Therapeutics Corporation (acquired by Biogen Idec, Inc. (Biogen) in 2006) in 2000 and Aarden Pharmaceuticals Inc. in 2008. From 2009 to 2015, he served as Head of Oncology Biology at Tragara Pharmaceuticals Inc., a biotechnology company. From 2006 to 2008, Dr. Burrows served as Senior Director of Molecular Discovery at Biogen, where he was responsible for one clinical, two preclinical and four discovery programs and also initiated efforts to use Hsp90 inhibitors in neurodegenerative and autoimmune conditions. Dr. Burrows earned his Ph.D. in Immunology from University of Bristol and his B.Sc. in Zoology from University of Durham.

Teresa Bair, J.D. has served as our Chief Legal Officer and Secretary since October 2021. Ms. Bair joined Kura with more than 25 years of combined in-house and law firm experience, serving most recently as General Counsel and Senior Vice President, Administration at Athenex Inc, from 2015 to October 2021, where she helped lead the organization through its evolution from a private, preclinical-stage company to a global, publicly traded biopharmaceutical company, directly contributing to multiple new drug application filings and an FDA approval. Previously, she was a partner at Harris Beach PLLC from 1999 to 2015, advising business clients, including Fortune 500 companies, across diverse industries on commercial litigation matters. Ms. Bair serves on the Boards of Directors of the University of Buffalo Foundation, the Bowling Green State University Foundation, and BirchBioMed Inc., a privately held biomedical company. Ms. Bair previously served on the Board of Directors of Infinite Group, Inc., a publicly traded cybersecurity company, from January 2022 to October 2023. She earned her J.D. from State University of New York at Buffalo School of Law and her B.S. in business administration from Bowling Green State University.